Get the Stockscreener App
1.40
6.04%
-0.09
Co Diagnostics Inc stock is traded at $1.40, with a volume of 327.41K.
It is down -6.04% in the last 24 hours and down -45.53% over the past month.
Co-Diagnostics Inc is a molecular diagnostics company. The company develops, manufactures, licenses, and commercializes reagents used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules (DNA or RNA), including molecular tools for detection of infectious diseases. CDI's low-cost system uses its tests to diagnose tuberculosis, Zika, hepatitis B and C, Malaria, dengue and others. The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious diseases.
See More
Previous Close:
$1.49
Open:
$1.45
24h Volume:
327.41K
Relative Volume:
0.06
Market Cap:
$5.16M
Revenue:
$513.90K
Net Income/Loss:
$-48.50M
P/E Ratio:
-0.05
EPS:
-28.0101
Net Cash Flow:
$-28.99M
1W Performance:
-7.89%
1M Performance:
-45.53%
6M Performance:
-64.22%
1Y Performance:
-87.42%
1-Day Range:
$1.36
$1.471
1-Week Range:
$1.36
$1.575
52-Week Range:
$1.26
$13.54
Co Diagnostics Inc Stock (CODX) Company Profile
Name
Co Diagnostics Inc
Sector
Industry
Phone
(801) 438-1036
Address
2401 S FOOTHILL DRIVE, SALT LAKE CITY
Compare CODX vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CODX
Co Diagnostics Inc
|
1.40 | 5.45M | 513.90K | -48.50M | -28.99M | -28.01 |
ABT
Abbott Laboratories
|
111.25 | 191.92B | 46.59B | 5.41B | 7.38B | 3.0938 |
SYK
Stryker Corp
|
339.21 | 133.18B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
91.27 | 116.18B | 36.36B | 4.84B | 5.43B | 3.7261 |
BSX
Boston Scientific Corp
|
51.83 | 74.52B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
91.60 | 53.63B | 6.30B | 1.07B | 1.09B | 1.8406 |
Co Diagnostics Inc Stock (CODX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-12-22 | Downgrade | Sidoti | Buy → Neutral |
| Dec-29-21 | Initiated | Sidoti | Buy |
| Mar-29-21 | Downgrade | Maxim Group | Buy → Hold |
| May-20-20 | Upgrade | Maxim Group | Hold → Buy |
| May-18-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-09-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-03-20 | Downgrade | Maxim Group | Buy → Hold |
View All
Co Diagnostics Inc Stock (CODX) Latest News
Co-Diagnostics Inc (CODX) Stock News Today - TradingKey
Armistice Capital discloses 9.99% Co-Diagnostics (CODX) holding via Master Fund - Stock Titan
Co-diagnostics(CODX) Stock Options Chain | Quotes & News - Moomoo
CODX|Co-Diagnostics Inc|Price:1.460|Chg%:-0.020 - TradingKey
Co-Diagnostics (CODX) Earnings Call Q2 2026: FDA-Antrag schreitet voran, während Barmittel sinken - TradingKey
Co-Diagnostics (CODX) Q2 2026 Earnings Call: FDA Filing Advances as Cash Falls - tradingkey.com
Co-Diagnostics Inc (CODX) (Q2 2026) Earnings Call Highlights: FD - GuruFocus
Is Co-Diagnostics Inc (CODX) Undervalued Despite Q2 Earnings Mis - GuruFocus
Co-Diagnostics Q2 Results: Net loss narrows to $6.3 million - scanx.trade
Co-Diagnostics Reports Q2 2026 Results: Full Earnings Call Transcript - benzinga.com
Earnings call transcript: Co-Diagnostics narrows loss in Q2 2026 but revenue stays thin - Investing.com
Co-Diagnostics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Co-Diagnostics (CODX) Stock Falls on Q2 2026 Earnings - Quiver Quantitative
CODX Stock Explodes Over 630% In Six Sessions – Retail Traders Bet The Rally Isn’t Over Yet - Stocktwits
Co-Diagnostics Q2 2026 Earnings: Losses Narrow as Revenue Stays Near $0.17 Million - TradingKey
Co-Diagnostics (CODX) posts Q2 loss and flags going concern, raises new equity - Stock Titan
Co-Diagnostics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Co-Diagnostics Q2 revenue rises slightly amid international expansion - TradingView
Co-Diagnostics, Inc. (CODX) Latest Stock News & Headlines - Yahoo Finance
Co-Diagnostics Reports Second Quarter 2026 Financial Results - PR Newswire
CODX Q2'26 Earnings: EPS estimate is (3.00) USD - TradingView
Co-Diagnostics Inc expected to post a loss of $3.00 a shareEarnings Preview - TradingView
Why Did CODX Stock Nearly Double In Value Today? - Stocktwits
Co-Diagnostics (NASDAQ: CODX) sees Jane Street disclose 1.7% equity stake - Stock Titan
Co-Diagnostics Inc (CODX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
CODX Stock Price, Quote & Chart - ChartMill
Co-Diagnostics submits FDA 510(k) for respiratory test By Investing.com - Investing.com South Africa
CODX Looks 28.1% Undervalued on GF Value™ Amid Challenging Finan - GuruFocus
Co-Diagnostics submits FDA application for dece... - Pluang
Co-Diagnostics submits FDA 510(k) for respiratory test - Investing.com
Co-Diagnostics Submits FDA 510(k) Premarket Notification for Upper Respiratory Point-of-Care Test - TradingView
CODX Q2'26 Earnings: revenue estimate is 132.58K USD - TradingView
Weekly Recap: Co-Diagnostics, Inc. Q2 results date and Bundibugyo test - TradingView
Co-Diagnostics Raises Capital Through Warrant Inducement Ahead of FDA Review - The Clinical Trial Vanguard
Why Is Co-Diagnostics (NASDAQ:CODX) In Focus After Its Latest Molecular Diagnostics Update? - Kalkine Media
Co-Diagnostics holders exercise 1,702,362 warrants at USD 1.57 per share in inducement deal - Bitget
Co-Diagnostics Plans Aug. 13 Webcast on Second-Quarter Results - Stock Titan
Co-Diagnostics Inc (CODX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
EXCLUSIVE: Co-Diagnostics Announces Successful Proof of Concept for Extraction-Free Ebola Test - Yahoo Finance
CODX Looks 3.8% Undervalued on GF Value™ as Market Prices in Cha - GuruFocus
Co-Diagnostics Joint Venture CoSara provides Ebola Test Kits for analytical studies - BioSpectrum Asia
Co-Diagnostics Joint Venture CoSara Provides Ebola Test Kits for Analytical Studies - PR Newswire
Co-Diagnostics, Inc. Announces Amendment to Equity Distribution Agreement with Maxim Group LLC – July 2026 SEC Filing Update – Minichart - Minichart
Co-DiagnosticsAmends Equity Distribution Agreement With Maxim Group For Common Stock SaleSEC Filing - TradingView
Co-Diagnostics Updates ATM With Maxim, Extends Share Standstill to Aug. 14, 2026 - TradingView
Co-Diagnostics Inc (CODX) Cash Flow - TradingKey
Co-Diagnostics Inc (CODX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Co-Diagnostics Inc (CODX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Co-Diagnostics Inc (CODX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Co-Diagnostics, Inc. Revenue Breakdown – MUN:C970 - TradingView
CODX|Co-Diagnostics Inc|Price:2.100|Chg%:-0.110 - TradingKey
Co Diagnostics Inc Stock (CODX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.08%
1.18%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):